

Notice of Organizational Changes and Consolidation of U.S. Subsidiaries in Vascular Division

1. Overview

NIPRO CORPORATION (Head office: Settsu, Osaka; President: Tsuyoshi Yamazaki) announces the following effective April 1, 2026.

- The "Global Vascular Headquarters" which is responsible for expanding sales of vascular products in global markets, will be transferred from the Global Business Division to the Vascular Division.
- In addition, consolidated subsidiaries Avantec Vascular Corporation ("Avantec") and Infraredx, Inc. ("Infraredx") will be merged, and the corporate name will be changed to NIPRO Vascular Innovations Americas, Inc.

2. Purpose

The NIPRO Group positions the vascular field as one of its key growth areas. In order to accelerate the global expansion of the vascular business, the Company aims to introduce the high value-added product portfolio of the Vascular Division to global markets more rapidly. Furthermore, by establishing an integrated end-to-end structure that accurately reflects market needs in business operations and product development, the Company seeks to create new value required by patients and healthcare professionals.

In the vascular business, the NIPRO Group aims to provide new value to clinical settings from both diagnostic and therapeutic perspectives. By consolidating Avantec, which is responsible for R&D in the therapeutic field, and Infraredx, which has strengths in the diagnostic field, the Company aims to generate synergies through cross-functional R&D activities in both diagnosis and treatment.

In addition, through this corporate name change, the Company expects to further enhance the presence of the NIPRO brand.

3. Effective Date

April 1, 2026

4. Impact on Financial Results

As this involves organizational changes and subsidiary reorganization within the NIPRO Group, the impact on financial results is expected to be minimal.

5. Overview of the New Subsidiary

- (1) Company Name: NIPRO Vascular Innovations Americas, Inc.
- (2) Locations:
 - East Innovation Center (Bedford, Massachusetts – current Infraredx location)
 - West Innovation Center (Sunnyvale, California – current Avantec location)
- (3) Representative: Jack Hoshino (President & CEO) *Current President of Avantec
- (4) Date of Corporate Name Change: April 1, 2026 (planned)
- (5) Business Activities: Research and development of diagnostic and therapeutic products in the vascular field.

About Infraredx

Infraredx is advancing the diagnosis and management of coronary artery disease as an industry leader in catheter based intravascular near-infrared spectroscopy and high-definition ultrasound. Its flagship products are approved and available in over 60 global markets. For more information, please visit www.infraredx.com.

About Avantec

Avantec is committed to medical device innovation in the vascular and endovascular space, aligning with NIPRO Medical Corporation to bring patients in the United States and across the globe simple, innovative solutions to complex issues affecting their vascular health. For more information, please visit www.avantecvascular.com.

This news release is meant to provide information on NIPRO's corporate activities and an overview of our initiatives to not only the press but also our many stakeholders, including shareholders and investors in a fair and timely manner.

The information about NIPRO products and services included in this release is not intended for use in attracting customers or as medical advice.

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.